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Copper Accumulation and the Effect of 
Chelation Treatment on Cerebral Amyloid 
Angiopathy Compared to Parenchymal 
Amyloid Plaques 
Xiayoue Zhua,b, Tiffany W. Victorc, Ashwin Ambic,d, Joseph K. 
Sullivana,¶, Joshua Hatfielda,b,§, Feng Xu1a,b Lisa M. Millerc,d and 
William E. Van Nostrand1a,b* 
Accumulation of fibrillar amyloid -protein (A) in parenchymal plaques 
and in blood vessels of the brain, the latter condition known as cerebral 
amyloid angiopathy (CAA), are hallmark pathologies of Alzheimer’s disease 
(AD) and related disorders. Cerebral amyloid deposits have been reported 
to accumulate various metals, most notably copper and zinc. Here we show 
that, in human AD, copper is preferentially accumulated in amyloid-
containing brain blood vessels compared to parenchymal amyloid plaques. 
In light of this observation, we evaluated the effects of reducing copper 
levels in Tg2576 mice, a transgenic model of AD amyloid pathologies. The 
copper chelator, tetrathiomolybdate (TTM), was administered to twelve 
months old Tg2576 mice for a period of five months. Copper chelation 
treatment significantly reduced both CAA and parenchymal plaque load in 
Tg2576 mice. Further, copper chelation reduced parenchymal plaque 
copper content but had no effect on CAA copper levels in this model. These 
findings indicate that copper is associated with both CAA deposits and 
parenchymal amyloid plaques in humans, but less in Tg2576 mice. TTM only 
reduces copper levels in plaques in Tg2576 mice. Reducing copper levels in 
brain may beneficially lower amyloid pathologies associated with AD. 
Introduction 
Cerebral amyloid angiopathy (CAA) is a common cerebral small 
vessel disease that involves the accumulation of amyloid -
protein (A) primarily in small- and medium-sized arteries and 
arterioles of the meninges and cerebral cortex as well as along 
the capillaries of the cerebral microvasculature1-4. CAA has been 
shown to be present, in varying degrees, in nearly 80% of elderly 
individuals5, 6. With the involvement of A, it is not surprising 
that CAA is a very common vascular comorbidity in patients with 
Alzheimer’s disease (AD)3, 4. Independent of AD, CAA is a 
significant contributor to vascular-mediated cognitive 
impairment and dementia (VCID)2, 7. CAA can uniquely 
contribute to the cognitive decline in VCID and AD in several 
ways. For example, the accumulation of amyloid in cerebral 
blood vessels causes degeneration of cerebrovascular smooth 
muscle cells and microvascular pericytes8-10. Also, CAA 
promotes the increased expression and activation of certain 
proteolytic enzymes in cerebral vascular cells11-13. Together, 
these processes can lead to loss of vessel wall integrity and 
hemorrhage and/or chronic hypoperfusion and ischemic 
infarcts2, 14-18. Yet, the reasons why cerebral vascular amyloid 
develops and its contribution to downstream pathologies and 
VCID remain unclear. 
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Copper is an essential metal for normal brain development 
and function as it is an important co-factor for a number of 
enzymes and mitochondrial respiration19-21. Altered brain 
copper homeostasis has been considered to be a factor in the 
pathogenesis of AD, but little is understood about the specific 
mechanisms of action22. On one hand, there have been reports 
of low plasma copper levels in AD23, 24. Alternatively, other 
studies have reported elevated levels of plasma copper in AD25, 
26. In particular, several studies have reported the accumulation 
of copper ions in amyloid plaque deposits of AD patients and in 
certain mouse models of parenchymal AD-like plaques27-30. 
Further, several single nucleotide polymorphisms in the copper 
transporter ATP7B gene are associated with a significant 
increase in the risk for the development of AD31-33. These 
findings suggest that copper accumulation in parenchymal 
amyloid plaques may be correlated with neurodegeneration 
and cognitive impairment.   
Mechanistically, this hypothesis is supported by in vitro 
studies that demonstrated that copper binds to A, presumably 
through three N-terminal histidine residues, resulting in a 
reduction of Cu2+ to Cu+34. Copper-bound A has been shown to 
be more prone to aggregation35 and also reacts with oxygen to 
produce reactive oxygen species that can promote 
neurodegeneration and thus cause cognitive impairment36. 
Specifically, copper-binding to Aβ has been shown to result in 
hydroxyl radical formation and the production of hydrogen 
peroxide, which activate a pro-inflammatory response in the 
form of interleukin-1β and tumor necrosis factor-α, which 
further contributes to neurodegeneration37{Kitazawa, 2016 #1435}. 
Collectively, these studies suggest that copper may play an 
important role in both the formation of amyloid plaques and in 
subsequent neuronal dysfunction and cognitive impairment. In 
contrast to previous work examining parenchymal amyloid 
plaques, comparatively little is known about the accumulation 
of copper in cerebral vascular amyloid deposits, which are 
associated with VCID. 
Here we report that CAA deposits contain higher copper 
levels than parenchymal amyloid plaques in human AD brain. 
We then hypothesized that copper plays a role in promoting 
and/or stabilizing fibrillar amyloid deposition in CAA. Chronic 
treatment of Tg2576 mice, a model of AD-like amyloid 
pathologies, with the copper chelator TTM lowered the amount 
of both cerebral vascular amyloid and parenchymal plaque 
amyloid deposition. Further, TTM lowered the levels of copper 
present only in parenchymal plaques and had no effect on CAA 
copper levels. However, in Tg2576 mice, the copper level in 
parenchymal plaques was modestly higher than in CAA 
deposits, a finding distinct from human CAA. Nevertheless, the 
present findings show that copper is strongly associated with 
cerebral vascular amyloid and may play a role in amyloid 
formation and subsequent CAA pathologies. 
 
Materials and Methods 
Human AD brain tissues  
Fresh frozen human AD brain tissue specimens containing both 
parenchymal plaques and cerebral vascular amyloid were obtained 
from the Neuropathology Core at University of California University 
of California, Irvine. 
Animal experiments 
All work with animals was approved by the University of Rhode Island 
and Stony Brook University Institutional Animal Care and Use 
Committees and were conducted in conformity with the NIH Guide 
for Care and Use of Laboratory Animals.  
Tg2576 mice were obtained from Jackson Laboratories at 
approximately three months of age and housed in a controlled room 
(22 ± 2°C) with a 12h reverse light-dark cycle. At twelve months of 
age cohorts of Tg2576 mice were administered drinking water 
containing 5% sucrose (control) or 10mg/ml ammonium 
tetrathiomolymbdate (TTM) (copper chelator) + 5% sucrose for a 
period of five months. All administrations were prepared fresh and 
replaced every third day. Weekly water consumption and monthly 
body weights were determined for each animal in the study.  
Brain tissue collection and preparation  
Mice were euthanized at the end of the study and perfused with 
cold-PBS, forebrains were removed and dissected through the mid-
sagittal plane. One hemisphere was flash frozen in liquid nitrogen 
and stored at -80 oC. For immunohistochemical studies, the other 
hemisphere was immersion-fixed with 70% ethanol overnight and 
subjected to increasing sequential dehydration in ethanol, followed 
by xylene treatment and embedding in paraffin. Sagittal sections 
were cut through the entire hemisphere at 10 µm thickness using a 
Leica RM2135 microtome (Leica Microsystems Inc., Bannockburn, 
IL), placed in a flotation water bath at 40°C, and then mounted on 
Colorfrost/Plus slides (Fisher Scientific, Houston, TX). 
X-ray fluorescence microscopy 
For XFM studies, fresh frozen human AD brain tissue (n=3) and 
Tg2576 mouse brain tissue (n=3 treated with TTM, n=3 untreated) 
were sectioned at 20 µm and mounted on 4-µm-thick Ultralene film, 
which was affixed to a 1.5” diameter Delrin ring. The localization of 
amyloid was determined by staining the tissue sections with 
thioflavin S. Prior to XFM data collection, the protein density in the 
vessels was determined using Fourier transform infrared 
microspectroscopy (FTIRM). Since the vessels can be denser than the 
surrounding tissue, the protein density was used to normalize the 
XFM data when quantifying the metal content, thus avoiding an 
overestimate of the metal content within the vessels. FTIRM spectra 
were acquired using a Spectrum Spotlight FTIR microscope with 8 cm-
1 spectral resolution over the mid-infrared spectral region (4000-800 
cm-1). A 20 µm aperture was used with 64 scans per point. The 
relative protein content at each pixel was determined by integrating 
the Amide II protein peak from 1490 – 1580 cm-1 with a linear 
baseline from 1480 – 1800 cm-1. The area under this peak is directly 
proportional to the amount of protein in the specimen. The relative 
protein density was calculated as the Amide II area on/off the 
vessels.  
The copper concentration within the vessels and plaques was 
determined using synchrotron XFM at beamline 13-ID-E at the 
Advanced Photon Source, Argonne National Laboratory and 
beamlines 4-BM and 5-ID at the National Synchrotron Light Source II, 
Brookhaven National Laboratory. The energy of the incident X-ray 
beam was 10 keV. The X-ray beam was focused to a 1-3 µm spot size 
using Kirkpatrick-Baez focusing mirrors. X-ray fluorescence was 
detected by a Si-drift detector oriented at a 90° angle from the 
incident beam. Energy dispersive spectra were collected at every 
pixel. 
Quantitation of A peptides  
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Total cerebral levels of Aβ40 and Aβ42 were determined by 
performing specific ELISAs on mouse forebrain tissue homogenates 
as described38, 39. In the sandwich ELISAs Aβ40 and Aβ42 were 
captured using their respective carboxyl-terminal specific antibodies 
mAb2G3 and mAb21F12 and biotinylated m3D6, specific for human 
Aβ, was used for detection. Each mouse brain homogenate was 
measured in triplicate and compared to linear standard curves 
generated with known concentrations of human Aβ using a 
Spectramax M2 plate reader (Molecular Devices, Sunnyvale, CA).  
Immunohistochemical analysis  
Antigen retrieval was performed by treating the tissue sections with 
proteinase K (0.2 mg/ml) for 10 min at 22 °C. Primary rabbit 
polyclonal antibody to collagen type IV was used to visualize cerebral 
vessels (1:100; ThermoFisher, Rockford, IL). The primary antibody 
was detected with Alexa Fluor 594-conjugated donkey anti-rabbit 
secondary antibody (1:1000). Staining for fibrillar amyloid was 
performed using thioflavin S. Brain tissue sections were imaged and 
collected using an Olympus BX60 microscope with an attached 
Olympus Dp72 camera. Images were collected from every tenth 
section spanning the hemisphere. 
Quantitative analysis of amyloid pathologies  
Using NIH ImageJ software, the percent area occupied with positive 
stain was quantified. Percent area coverage of ThS+ parenchymal 
plaques and ThS+ amyloid on blood vessels in the cortical regions was 
determined. 
Statistical Analysis  
XFM, histological and immunochemical data were analyzed by t-test 
at the 0.05 significance level.  
Results 
Cerebral vascular amyloid contains elevated copper levels 
compared with parenchymal amyloid plaques in AD brain 
Previous studies have reported that amyloid plaques in human AD 
brain accumulate metal ions including iron, copper, and zinc 29, 30. 
Here we sought to determine whether cerebral vascular amyloid 
deposits similarly accumulate metal ions using the technique of x-ray 
fluorescence microscopy (XFM). Fig. 1A and 1B show representative 
thioflavin S stained images of fibrillar parenchymal amyloid plaques 
and fibrillar cerebral vascular amyloid deposits, respectively. Fig. 1C 
and 1D show the same deposits imaged for copper using XFM 
demonstrating the elevated levels of copper in the CAA deposits. 
Statistically, Fig. 1E shows that the copper content is ~3-fold higher 
in vascular amyloid deposits when compared to plaques in human 
AD brain tissue (p < 0.03). A similar trend was observed with the zinc 
content, which showed that zinc was 2-3 times higher in the CAA 




Fig. 1.  Higher copper content in cerebral vascular amyloid deposits compared 
to parenchymal plaque amyloid deposits in the same AD brain tissue. 
Epifluorescence images of the thioflavin S staining and corresponding copper 
XFM images of parenchymal (A,C) and cerebral vascular (B,D) amyloid 
deposits from the same AD brain tissue. Scale bars = 5 µm. (E) Relative copper 
levels in the vascular amyloid deposits were ~3-fold higher than in 
parenchymal amyloid plaques. Data shown are mean ± S.D. of n = 5 for each 
type of amyloid deposit from the same tissues.   
 
Administration of the copper chelator TTM to Tg2576 mice with AD-
like amyloid pathologies 
To investigate if copper levels impact CAA and amyloid plaque 
pathology in Tg2576 mice, we administered TTM through their 
drinking water starting at twelve months of age, a point where both 
cerebral vascular and parenchymal amyloid pathologies begin to 
emerge in this model40, 41 Tg2576 mice were administered drinking 
water containing either 5% sucrose + 10 mg/ml of the copper 
chelator TTM or 5% sucrose alone for a period of five months. Weekly 
water intake from each group of animals was not significantly 
different (control = 214 ± 91 vs TTM = 171 ± 60; p = 0.2). Likewise, 
both groups of Tg2576 mice started at similar weights (control = 32.2 
± 5.1 vs TTM = 29.7 ± 6.1: p = 0.3) and finished the study at similar 
weights (control = 39.1 ± 6.6 vs TTM = 33.5 ± 6.2; p = 0.06). Thus, 
administration of TTM had no adverse effect on the general health 
of the Tg2576 mice. 
Copper chelation with TTM reduces cerebral vascular amyloid and 
parenchymal plaque load in Tg2576 mice 
 Accumulation and deposition of A peptides in the brain is a key 
pathological feature of AD that is replicated in Tg2576 transgenic 
mice 40. Since we observed the presence of copper in cerebral 
amyloid deposits in human AD brain (Fig. 1), we investigated the 
effects of copper chelation on A accumulation in Tg2576 mice. 
ELISA measurements for the total levels of forebrain A40 and A42 
peptides revealed no significant difference between control and 
TTM-treated Tg2576 mice (Fig. 2). Although copper chelation 
treatment did not significantly affect the total cerebral accumulation 
of A species we next evaluated the impact on compartmental 
deposition of amyloid in the brains of the Tg2576 mice. 
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Fig. 2.  ELISA analysis of cerebral A40 and A42 peptides in control and TTM-
treated Tg2576 mice. The total levels of A40 peptides (black bars) and A42 
peptides (gray bars) in the forebrains of control and TTM-treated Tg2576 mice 
were measured by ELISA as described under “Materials and Methods.” The 
data presented are the means ± S.D. of triplicate measurements of n = 5-6 
mice per group.   
Staining for fibrillar amyloid deposition using thioflavin S 
revealed the presence of cortical CAA, mainly in the surface 
meningeal vessels. Morphologically there was no discernible 
difference between the appearance of CAA in the control and TTM-
treated Tg2576 mice (Fig. 3A and 3B, respectively). However, 
quantifying the amount of cortical CAA revealed a significant 
reduction (p < 0.05) in the amount of vessel coverage with amyloid 
in the TTM-treated Tg2576 mice (Fig. 3C). Similarly, staining for 
fibrillar amyloid showed the presence of parenchymal plaques in 
both control and TTM-treated Tg2576 mice (Fig. 4A and 4B, 
respectively). Again, there was no apparent difference in the 
morphology of the fibrillar amyloid plaques. Yet, similar to the 
findings with CAA, there was a significant reduction (p < 0.05) in 
percentage of cortical area occupied by fibrillar amyloid plaques (Fig. 
4C). Together, these findings indicate that copper chelation with TTM 
treatment reduced the amount of both fibrillar CAA and 
parenchymal plaque amyloid deposition in Tg2576 mice. 
 
Fig. 3.  TTM treatment reduces CAA load in Tg2576 mice. Brain sections from 
control (A) and TTM-treated (B) Tg2576 mice were stained for fibrillar amyloid 
using thioflavin-S (green) and immunolabeled for collagen type IV to identify 
cerebral blood vessels (red). Scale bars = 50 µM. (C) Quantitation of cortical 
vascular thioflavin-S positive amyloid load in control and TTM-treated Tg2576 
mice. Data shown are mean ± S.D. of n = 5 Tg2576 mice per group.    
 
Fig. 4.  TTM treatment reduces cortical amyloid plaque load in Tg2576 mice. 
Brain sections from control (A) and TTM-treated (B) Tg2576 mice were 
stained for fibrillar amyloid using thioflavin-S (green) and immunolabeled for 
collagen type IV to identify cerebral blood vessels (red). Scale bars = 50 µM. 
(C) Quantitation of cortical thioflavin-S positive amyloid plaque load in control 
and TTM-treated Tg2576 mice. Data shown are mean ± S.D. of n = 5 Tg2576 
mice per group. 
Copper chelation with TTM reduces copper content of parenchymal 
amyloid plaques but not of CAA in Tg2576 mice 
Since copper chelation treatment lowered both CAA and 
parenchymal plaque load in the Tg2576 mice, we next determined if 
this treatment also changed the copper content in these distinct 
cerebral amyloid lesions. We performed XFM on CAA and 
parenchymal amyloid plaque deposits in control and TTM-treated 
Tg2576 mice that were identified by staining with thioflavin S (Fig. 5).  
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Fig. 5.  TTM treatment reduces cortical amyloid plaque copper levels in 
Tg2576 mice. Brain sections from control and TTM-treated Tg2576 mice were 
stained with thioflavin S to identify fibrillar amyloid deposits in cerebral 
vessels (V) and parenchymal amyloid plaques (P). The relative copper levels 
in these deposits were determined using XFM and tissue density was 
normalized using FTIR microspectroscopy. All Cu images are shown on the 
same intensity scale. Histograms shown are mean ± S.D. of n = 5 Tg2576 mice 
per group. 
Interestingly, we found that the copper content in parenchymal 
amyloid plaques was significantly higher (p < 0.01) than the cerebral 
vascular amyloid deposits in Tg2576 mice, which was the opposite of 
what was observed in human AD brain tissue (Fig. 1). TTM treatment 
significantly lowered (p < 0.01) the copper content of parenchymal 
amyloid plaques but had no effect on reducing the copper content of 
CAA deposits. At the end of TTM treatment, the copper content of 
vascular and parenchymal amyloid deposits was essentially the 
same. These findings indicate that although TTM treatment similarly 
reduces CAA and parenchymal plaque load it only lowers copper 
content in the parenchymal amyloid plaques in Tg2576 mice.  
Discussion 
CAA is a common cerebral small vessel disease of the elderly and a 
prominent comorbidity of AD that promotes and exacerbates VCID, 
yet our understanding of the condition remains limited. Both CAA 
and AD are characterized by the accumulation of fibrillar Aβ in the 
brain vessels and parenchyma, respectively. In human AD, metal ions 
including iron, copper, and zinc have been shown to co-localize with 
the parenchymal plaques 29, 30. But while the parenchymal plaques in 
AD have been studied extensively, little is known about metal-ion 
accumulation in amyloid-containing brain vessels in AD. Here we 
examined the cerebral vascular amyloid in human AD and found that 
the copper content was ~3-fold higher than the parenchymal plaques 
and >10-fold higher than surrounding brain tissue. This finding 
supports the hypothesis of an environment for toxic redox chemistry 
in the vessel walls, leading to pro-inflammatory responses that may 
play a role in the degeneration of cerebrovascular cells, which can 
lead to loss of vessel wall integrity and subsequent CAA 
pathologies37, 42. 
In contrast to human AD, the PSAPP and 5XFAD mouse models of 
AD show little or no metal accumulation in the parenchymal plaques 
27, 28. Results presented here for the Tg2576 mouse model show 
similar results. Given the similarly low copper levels in parenchymal 
plaques from all mouse models, and the observations that mouse 
models also show much less neuronal loss than humans, it has been 
suggested that copper binding to Aβ plaques generates redox-
initiated toxic species that contribute to neurodegeneration.  
Unlike previous work that focused only on parenchymal plaques, 
this is the first study to examine both parenchymal plaques and 
vascular amyloid in the same animals. Results show that, for the 
Tg2576 mouse model, the copper-binding in both plaques and 
vessels is considerably lower than what has been observed in 
humans and, surprisingly, parenchymal plaques have a slightly higher 
copper content than the vascular amyloid. Studies on vascular and 
parenchymal amyloid have shown that the primary Aβ species in the 
vasculature is Aβ40, whereas the parenchymal plaques contain 
primarily Aβ42 3, 4. Further, recent studies have shown that in 
vascular amyloid the fibrils possess an anti-parallel configuration that 
is distinct from the parallel fibril orientation observed in 
parenchymal plaques. Thus, we suggest that peptide length and/or 
structural differences between vascular and parenchymal Aβ fibrils 
may affect copper-binding. 
 Given the potential role of copper in CAA pathogenesis, we 
assessed whether copper chelation treatment would alleviate the 
amyloid burden in the brain vasculature and parenchyma of Tg2576 
mice. We found that copper chelation treatment had no significant 
effect on the levels of cerebral A40 or A42 (Fig. 2). It has been 
shown that copper binds to the amyloid precursor protein (APP) 43 
and causes a reduction of Cu(II) to Cu(I) 44. Further binding of copper 
to APP can also modulate APP processing by γ-secretase and Aβ 
peptide production 45, 46. However, our finding of no significant effect 
of copper chelation on A  peptide levels in Tg2576 mouse brain 
suggests that this treatment is not appreciably impacting APP 
processing and Aβ production. 
Copper also binds to the Aβ peptide directly 47-51 where three 
histidine residues control the redox activity of the copper ion 52. 
Moreover, when bound to Aβ fibrils, copper redox chemistry can lead 
to the formation of hydrogen peroxide and generation of reactive 
oxygen species 37 and treatment with TTM has been shown to invoke 
anti-inflammatory responses53. In contrast to the ELISA measures of 
total cerebral A40 and A42 levels we show that the fibrillar 
vascular Aβ deposits and plaque burdens were both significantly 
reduced with copper chelation in the Tg2576 mice. This could suggest 
that copper plays a role in the formation and/or stabilization of the 
Aβ fibrils and, when copper is lowered, this results in reduced 
amyloid burden. 
 Even though the amyloid burden is lowered in both the vessels 
and plaques, the level of copper-binding in the amyloid that still 
forms is similarly low with or without the copper chelator. The only 
exception is the parenchymal plaques, which have a slightly higher 
level of copper-binding that is lowered by TTM. It is possible that the 
higher burden of parenchymal plaque amyloid compared to vascular 
amyloid in the Tg2576 mice provides more of a reservoir to bind 
copper in brain. Alternatively, since parenchymal plaques are 
primarily composed of Aβ42 3, 4, this could suggest that, in Tg2576 
mice, copper may preferentially bind Aβ42 fibrils compared to Aβ40 
fibrils and, when copper is lowered, results in decreased copper 
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binding in the parenchymal plaques. On the other hand, the inability 
of TTM to lower copper content in vascular amyloid may reflect 
stronger binding to these particular amyloid fibrils that were recently 
shown to possess a distinct anti-parallel structure 41.  
 In summary, we find that copper binding to CAA vessels is 
significantly higher than parenchymal plaques in human AD brain. 
Toxic redox chemistry associated with this higher level of copper in 
the vessels may contribute to degeneration of cerebral vascular cells 
and subsequent loss of vessel wall integrity. In contrast, the Tg2576 
mouse model of AD showed much lower levels of copper binding to 
amyloid in both the brain vessels and parenchymal plaques. 
Moreover, treatment with TTM had little effect on the copper 
content in the vessels or plaques in this model. Interestingly, 
however, TTM was shown to significantly reduce the amount of 
fibrillar amyloid in both the CAA vessels and parenchymal plaques. 
These findings suggest that chelation of copper in the Tg2576 mouse 
model may affect amyloid fibril formation and/or stabilization. 
However, in the CAA deposits and parenchymal plaques that still 
form, the copper content is considerably lower than the human 
condition, in agreement with earlier studies from other mouse 
models of AD. Together, this supports the hypothesis that redox 
chemistry associated with copper binding to Aβ results in the 
production of toxic species that contribute to cellular degeneration 
and these pathological processes are not robust in mouse models of 
AD. 
 
Conflicts of interest 
There are no conflicts to declare. 
Acknowledgements 
This work was supported by NIH grant NS094201 to WEVN and 
LMM. Antibody reagents for the A ELISA were generously 
provided by Lilly Research Laboratories, Indianapolis, IN. 
Portions of this work were performed at GeoSoilEnviroCARS 
(The University of Chicago, Sector 13), Advanced Photon Source 
(APS), Argonne National Laboratory. GeoSoilEnviroCARS is 
supported by the National Science Foundation - Earth Sciences 
(EAR - 1634415) and Department of Energy- GeoSciences (DE-
FG02-94ER14466). This research used resources of the 
Advanced Photon Source, a U.S. Department of Energy (DOE) 
Office of Science User Facility operated for the DOE Office of 
Science by Argonne National Laboratory under Contract No. DE-
AC02-06CH11357. This research also used beamlines 5-ID (SRX) 
and 4-BM (XFM) of the National Synchrotron Light Source II, a 
U.S. Department of Energy (DOE) Office of Science User Facility 
operated for the DOE Office of Science by Brookhaven National 
Laboratory under Contract No. DE-SC0012704. 
References[1] Banerjee G, Carare R, Cordonnier C, Greenberg SM, 
Schneider JA, Smith EE, Buchem MV, Grond JV, Verbeek MM, 
Werring DJ: The increasing impact of cerebral amyloid angiopathy: 
essential new insights for clinical practice. J Neurol Neurosurg 
Psychiatry 2017, 88:982-94. 
[2] Auriel E, Greenberg SM: The pathophysiology and clinical 
presentation of cerebral amyloid angiopathy. Curr Atheroscler Rep 
2012, 14:343-50. 
[3] Attems J, Jellinger K, Thal DR, Van Nostrand W: Review: sporadic 
cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2011, 
37:75-93. 
[4] Rensink AA, de Waal RM, Kremer B, Verbeek MM: Pathogenesis 
of cerebral amyloid angiopathy. Brain Res Brain Res Rev 2003, 
43:207-23. 
[5] Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, 
Schneider JA: Cerebral amyloid angiopathy and cognitive outcomes 
in community-based older persons. Neurology 2015, 85:1930-6. 
[6] Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, 
Schneider JA: Cerebral amyloid angiopathy pathology and cognitive 
domains in older persons. Ann Neurol 2011, 69:320-7. 
[7] Greenberg SM, Gurol ME, Rosand J, Smith EE: Amyloid 
angiopathy-related vascular cognitive impairment. Stroke 2004, 
35:2616-9. 
[8] Kawai M, Kalaria RN, Cras P, Siedlak SL, Velasco ME, Shelton ER, 
Chan HW, Greenberg BD, Perry G: Degeneration of vascular muscle 
cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res 
1993, 623:142-6. 
[9] Davis-Salinas J, Saporito-Irwin SM, Cotman CW, Van Nostrand 
WE: Amyloid beta-protein induces its own production in cultured 
degenerating cerebrovascular smooth muscle cells. J Neurochem 
1995, 65:931-4. 
[10] Verbeek MM, de Waal RM, Schipper JJ, Van Nostrand WE: Rapid 
degeneration of cultured human brain pericytes by amyloid beta 
protein. J Neurochem 1997, 68:1135-41. 
[11] Van Nostrand WE, Porter M: Plasmin cleavage of the amyloid 
beta-protein: alteration of secondary structure and stimulation of 
tissue plasminogen activator activity. Biochemistry 1999, 38:11570-
6. 
[12] Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE: Amyloid 
beta-protein stimulates the expression of urokinase-type 
plasminogen activator (uPA) and its receptor (uPAR) in human 
cerebrovascular smooth muscle cells. J Biol Chem 2003, 278:19054-
61. 
[13] Jung SS, Zhang W, Van Nostrand WE: Pathogenic A beta induces 
the expression and activation of matrix metalloproteinase-2 in 
human cerebrovascular smooth muscle cells. J Neurochem 2003, 
85:1208-15. 
[14] Okamoto Y, Yamamoto T, Kalaria RN, Senzaki H, Maki T, Hase Y, 
Kitamura A, Washida K, Yamada M, Ito H, Tomimoto H, Takahashi R, 
Ihara M: Cerebral hypoperfusion accelerates cerebral amyloid 
angiopathy and promotes cortical microinfarcts. Acta Neuropathol 
2012, 123:381-94. 
[15] Samarasekera N, Smith C, Al-Shahi Salman R: The association 
between cerebral amyloid angiopathy and intracerebral 
haemorrhage: systematic review and meta-analysis. J Neurol 
Neurosurg Psychiatry 2012, 83:275-81. 
[16] Chung YA, O JH, Kim JY, Kim KJ, Ahn KJ: Hypoperfusion and 
ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD 
brain perfusion SPECT. J Nucl Med 2009, 50:1969-74. 
[17] Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith 
EE, Greenberg SM: Silent ischemic infarcts are associated with 
hemorrhage burden in cerebral amyloid angiopathy. Neurology 
2009, 72:1230-5. 
[18] Thanvi B, Robinson T: Sporadic cerebral amyloid angiopathy--an 
important cause of cerebral haemorrhage in older people. Age 
Ageing 2006, 35:565-71. 
[19] Skjorringe T, Moller LB, Moos T: Impairment of interrelated iron- 
and copper homeostatic mechanisms in brain contributes to the 
pathogenesis of neurodegenerative disorders. Front Pharmacol 
2012, 3:169. 
[20] Lutsenko S, Bhattacharjee A, Hubbard AL: Copper handling 
machinery of the brain. Metallomics 2010, 2:596-608. 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7  
Please do not adjust margins 
Please do not adjust margins 
[21] Gaggelli E, Kozlowski H, Valensin D, Valensin G: Copper 
homeostasis and neurodegenerative disorders (Alzheimer's, prion, 
and Parkinson's diseases and amyotrophic lateral sclerosis). Chem 
Rev 2006, 106:1995-2044. 
[22] Quinn JF, Crane S, Harris C, Wadsworth TL: Copper in Alzheimer's 
disease: too much or too little? Expert Rev Neurother 2009, 9:631-7. 
[23] Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman 
SM, Dick R: Copper and ceruloplasmin abnormalities in Alzheimer's 
disease. Am J Alzheimers Dis Other Demen 2010, 25:490-7. 
[24] Vural H, Demirin H, Kara Y, Eren I, Delibas N: Alterations of 
plasma magnesium, copper, zinc, iron and selenium concentrations 
and some related erythrocyte antioxidant enzyme activities in 
patients with Alzheimer's disease. J Trace Elem Med Biol 2010, 
24:169-73. 
[25] Arnal N, Cristalli DO, de Alaniz MJ, Marra CA: Clinical utility of 
copper, ceruloplasmin, and metallothionein plasma determinations 
in human neurodegenerative patients and their first-degree 
relatives. Brain Res 2010, 1319:118-30. 
[26] Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti 
S, Moffa F, Caridi I, Cassetta E, Pasqualetti P, Calabrese L, Lupoi D, 
Rossini PM: Excess of nonceruloplasmin serum copper in AD 
correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 
2006, 67:76-82. 
[27] Bourassa MW, Leskovjan AC, Tappero RV, Farquhar ER, Colton 
CA, Van Nostrand WE, Miller LM: Elevated copper in the amyloid 
plaques and iron in the cortex are observed in mouse models of 
Alzheimer's disease that exhibit neurodegeneration. Biomed 
Spectrosc Imaging 2013, 2:129-39. 
[28] Leskovjan AC, Lanzirotti A, Miller LM: Amyloid plaques in PSAPP 
mice bind less metal than plaques in human Alzheimer's disease. 
Neuroimage 2009, 47:1215-20. 
[29] Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy 
J: Synchrotron-based infrared and X-ray imaging shows focalized 
accumulation of Cu and Zn co-localized with beta-amyloid deposits 
in Alzheimer's disease. J Struct Biol 2006, 155:30-7. 
[30] Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery 
WR: Copper, iron and zinc in Alzheimer's disease senile plaques. J 
Neurol Sci 1998, 158:47-52. 
[31] Squitti R, Ventriglia M, Gennarelli M, Colabufo NA, El Idrissi IG, 
Bucossi S, Mariani S, Rongioletti M, Zanetti O, Congiu C, Rossini PM, 
Bonvicini C: Non-Ceruloplasmin Copper Distincts Subtypes in 
Alzheimer's Disease: a Genetic Study of ATP7B Frequency. Mol 
Neurobiol 2017, 54:671-81. 
[32] Squitti R, Siotto M, Arciello M, Rossi L: Non-ceruloplasmin bound 
copper and ATP7B gene variants in Alzheimer's disease. Metallomics 
2016, 8:863-73. 
[33] Squitti R, Polimanti R, Siotto M, Bucossi S, Ventriglia M, Mariani 
S, Vernieri F, Scrascia F, Trotta L, Rossini PM: ATP7B variants as 
modulators of copper dyshomeostasis in Alzheimer's disease. 
Neuromolecular Med 2013, 15:515-22. 
[34] Streltsov VA, Titmuss SJ, Epa VC, Barnham KJ, Masters CL, 
Varghese JN: The structure of the amyloid-beta peptide high-affinity 
copper II binding site in Alzheimer disease. Biophys J 2008, 95:3447-
56. 
[35] Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI: 
Trace metal contamination initiates the apparent auto-aggregation, 
amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J 
Biol Inorg Chem 2004, 9:954-60. 
[36] Eskici G, Axelsen PH: Copper and oxidative stress in the 
pathogenesis of Alzheimer's disease. Biochemistry 2012, 51:6289-
311. 
[37] Mayes J, Tinker-Mill C, Kolosov O, Zhang H, Tabner BJ, Allsop D: 
beta-amyloid fibrils in Alzheimer disease are not inert when bound 
to copper ions but can degrade hydrogen peroxide and generate 
reactive oxygen species. J Biol Chem 2014, 289:12052-62. 
[38] Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, 
Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert 
P, McConlogue L: Amyloid precursor protein processing and A beta42 
deposition in a transgenic mouse model of Alzheimer disease. Proc 
Natl Acad Sci U S A 1997, 94:1550-5. 
[39] DeMattos RB, O'Dell M A, Parsadanian M, Taylor JW, Harmony 
JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM: Clusterin promotes 
amyloid plaque formation and is critical for neuritic toxicity in a 
mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2002, 
99:10843-8. 
[40] Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, 
Yang F, Cole G: Correlative memory deficits, Abeta elevation, and 
amyloid plaques in transgenic mice. Science 1996, 274:99-102. 
[41] Xu F, Fu Z, Dass S, Kotarba AE, Davis J, Smith SO, Van Nostrand 
WE: Cerebral vascular amyloid seeds drive amyloid beta-protein fibril 
assembly with a distinct anti-parallel structure. Nat Commun 2016, 
7:13527. 
[42] Kitazawa M, Hsu HW, Medeiros R: Copper Exposure Perturbs 
Brain Inflammatory Responses and Impairs Clearance of Amyloid-
Beta. Toxicol Sci 2016, 152:194-204. 
[43] Hesse L, Beher D, Masters CL, Multhaup G: The beta A4 amyloid 
precursor protein binding to copper. FEBS Lett 1994, 349:109-16. 
[44] Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters 
CL, Beyreuther K: The amyloid precursor protein of Alzheimer's 
disease in the reduction of copper(II) to copper(I). Science 1996, 
271:1406-9. 
[45] Noda Y, Asada M, Kubota M, Maesako M, Watanabe K, Uemura 
M, Kihara T, Shimohama S, Takahashi R, Kinoshita A, Uemura K: 
Copper enhances APP dimerization and promotes Abeta production. 
Neurosci Lett 2013, 547:10-5. 
[46] Gerber H, Wu F, Dimitrov M, Garcia Osuna GM, Fraering PC: Zinc 
and Copper Differentially Modulate Amyloid Precursor Protein 
Processing by gamma-Secretase and Amyloid-beta Peptide 
Production. J Biol Chem 2017, 292:3751-67. 
[47] Kowalik-Jankowska T, Ruta-Dolejsz M, Wisniewska K, Lankiewicz 
L: Coordination of copper(II) ions by the 11-20 and 11-28 fragments 
of human and mouse beta-amyloid peptide. J Inorg Biochem 2002, 
92:1-10. 
[48] Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, 
Curtain CC, Williamson NA, White AR, Hinds MG, Norton RS, 
Beyreuther K, Masters CL, Parker MW, Cappai R: Structure of the 
Alzheimer's disease amyloid precursor protein copper binding 
domain. A regulator of neuronal copper homeostasis. J Biol Chem 
2003, 278:17401-7. 
[49] Syme CD, Nadal RC, Rigby SE, Viles JH: Copper binding to the 
amyloid-beta (Abeta) peptide associated with Alzheimer's disease: 
folding, coordination geometry, pH dependence, stoichiometry, and 
affinity of Abeta-(1-28): insights from a range of complementary 
spectroscopic techniques. J Biol Chem 2004, 279:18169-77. 
[50] Tougu V, Karafin A, Palumaa P: Binding of zinc(II) and copper(II) 
to the full-length Alzheimer's amyloid-beta peptide. J Neurochem 
2008, 104:1249-59. 
[51] Hatcher LQ, Hong L, Bush WD, Carducci T, Simon JD: 
Quantification of the binding constant of copper(II) to the amyloid-
beta peptide. J Phys Chem B 2008, 112:8160-4. 
[52] Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, 
Hayashi Y, Nakayama K, Hayashi T: Three histidine residues of 
ARTICLE Journal Name 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
amyloid-beta peptide control the redox activity of copper and iron. 
Biochemistry 2007, 46:12737-43. 
[53] Wang Z, Zhang YH, Guo C, Gao HL, Zhong ML, Huang TT, Liu NN, 
Guo RF, Lan T, Zhang W, Wang ZY, Zhao P: Tetrathiomolybdate 
Treatment Leads to the Suppression of Inflammatory Responses 
through the TRAF6/NFkappaB Pathway in LPS-Stimulated BV-2 
Microglia. Front Aging Neurosci 2018, 10:9. 
 
